Skip to main content

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Status
recruiting
Phase
Phase 3
Institution
Theresa Jacob, PhD, MPH
Principal investigator
Theresa Jacob, PhD, MPH
Start date
2024-10-16
End date
2027-09-30
Registry ID
NCT06752759

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.